Larimar completes Phase 2 50mg cohort enrollment; top-line data now Q1 2024; cash to Q1 2025

Larimar Therapeutics, Inc.

2023-Q3 EPS reported -$0.55

Completed enrollment and dosing of 50 mg cohort in Phase 2 FA trial; no serious adverse events observed (blinded).
Top-line safety, PK, and frataxin data now expected in Q1 2024, refined from H1 2024.
Open-label extension trial with 25 mg daily nomlabofusp on track for Q1 2024; interim data expected Q4 2024.
Cash, equivalents, and marketable securities of $95.6M as of Sep 30, 2023; projected runway into Q1 2025.
Q3 2023 net loss $9.1M ($0.21/share) vs $8.3M ($0.37/share) in Q3 2022; R&D expenses up to $6.6M.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Larimar Therapeutics, Inc. reported third quarter ended September 30, 2023 results: net income net loss of $9.1 million, or $0.21 per share, EPS ($0.21) per share.

Period: third quarter ended September 30, 2023
Net income: net loss of $9.1 million, or $0.21 per share
EPS: ($0.21) per share
Result: reported results

Exact text from the filing

Larimar Therapeutics, Inc. (the " Company ") announced its financial results and operational highlights for the third quarter ended September 30, 2023.

View on SEC.gov

Browse all earnings releases →

Larimar Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-063347

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.